Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.

Immunosuppression Increases Risk of HPV-related Cancers in AIDS Patients (8/20/2009)
The risk of HPV-related cancers is elevated among AIDS patients. This risk continues to increase as patients’ immune systems become more compromised, according to the results of a study published in the Journal of the National Cancer Institute.

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (5/1/2008)
Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published by the Journal of the American Medical Association.

Women with CIN at Higher Risk for Anal Cancer and Other Cancers (3/22/2007)
According to an early online publication in Lancet Oncology, women diagnosed with cervical intraepithelial neoplasia (CIN) grade 3 are at an increased risk of developing vaginal, vulvar, and anal cancers. Further research into the impact of the human papillomaviruses on these risks is underway.

5-FU/Mitomycin Remains Standard of Care for Anal Cancer (7/26/2006)
According to results recently reported at the 2006 semi-annual meeting of the Radiation Therapy Oncology Group (RTOG), treatment including the chemotherapy agents 5-fluorouracil and mitomycin-C (Mutomycin®) plus radiation therapy remains the standard of care for patients with anal cancer.

More Anal Cancer News »

Immunosuppression Increases Risk of HPV-related Cancers in AIDS Patients (8/20/2009)
The risk of HPV-related cancers is elevated among AIDS patients. This risk continues to increase as patients’ immune systems become more compromised, according to the results of a study published in the Journal of the National Cancer Institute.

Women with CIN at Higher Risk for Anal Cancer and Other Cancers (3/22/2007)
According to an early online publication in Lancet Oncology, women diagnosed with cervical intraepithelial neoplasia (CIN) grade 3 are at an increased risk of developing vaginal, vulvar, and anal cancers. Further research into the impact of the human papillomaviruses on these risks is underway.

New Colorectal Cancer Test Offers Hope for Early Detection (3/4/2002)
According to a report in the November issue of the journal Gastroenterology, early detection of colorectal cancer and precancerous tumors may be possible with a new screening test that involves looking for abnormal DNA in stool samples.

Selenium May Reduce Risk of Developing Lung, Colorectal, and Prostate Cancers (3/4/2002)
The essential dietary nutrient, selenium, may help reduce the risk of developing cancers of the lung, colon, rectum, and prostate, as well as reduce the number of deaths in persons who have certain types of cancer, according to preliminary research findings.

Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (5/1/2008)
Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published by the Journal of the American Medical Association.

5-FU/Mitomycin Remains Standard of Care for Anal Cancer (7/26/2006)
According to results recently reported at the 2006 semi-annual meeting of the Radiation Therapy Oncology Group (RTOG), treatment including the chemotherapy agents 5-fluorouracil and mitomycin-C (Mutomycin®) plus radiation therapy remains the standard of care for patients with anal cancer.

Radiation to the Pelvis Increases Risk of Pelvic Fractures (11/28/2005)
According to a recent article published in the Journal of the American Medical Association (JAMA), women who undergo radiation to the pelvis for cancers of the cervix, rectum, or anus are at an increased risk for pelvic fractures compared to women with these types of cancer who do not undergo pelvic radiation as part of their treatment regimen.

Intensive Chemotherapy and Radiation Therapy Combo May Improve Outcomes for Persons with Cancer of the Anus (2/5/2002)
Persons who have cancers of the anus that have spread to the nearby lymph nodes or are large in size may require more aggressive therapy than individuals with smaller cancers. Now, researchers say that chemotherapy with fluorouracil and cisplatin, followed by a combination of radiation therapy and chemotherapy with fluorouracil and mitomycin, may help preserve bowel function and improve survival for persons with this type of disease.

More Anal Cancer - Stages I-II News »

Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (5/1/2008)
Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published by the Journal of the American Medical Association.

5-FU/Mitomycin Remains Standard of Care for Anal Cancer (7/26/2006)
According to results recently reported at the 2006 semi-annual meeting of the Radiation Therapy Oncology Group (RTOG), treatment including the chemotherapy agents 5-fluorouracil and mitomycin-C (Mutomycin®) plus radiation therapy remains the standard of care for patients with anal cancer.

Treatment of Anal Cancer: Protective Drug, Called Amifostine, Reduces the Side Effects of Chemotherapy and Radiation Therapy (2/4/2002)
The side effects of chemotherapy and radiation therapy as treatment for anal cancer may be reduced with the use of a drug called amifostine, according to new research findings by German doctors.

Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.

Surgical Salvage Therapy is Effective Treatment for Patients with Rectal Cancer that Relapse Locally after Initial Sphincter-Conserving Treatment (2/5/2002)
The standard of care for most patients with anal cancer is now initial treatment with radiation or chemoradiotherapy, with the aim of preserving the anus and allowing sphincter function. With this approach, approximately 60-90% of patients can expect to have the cancer eradicated. The majority of these patients will be cured and continue to have a functioning anus.